In May 2022, the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group published a new review of the effects of cannabis and cannabinoids for the treatment of people with multiple sclerosis. In this podcast, Silvia Minozzi, Co-ordinating Editor of the Cochrane Drugs and Alcohol Group and an author on the review talks with lead author and Co-ordinating Editor of the Cochrane Multiple Sclerosis Group, Graziella Filippini, about the review.